Olema Pharmaceuticals (OLMA) risk factors, FY2024 10-K

Risks related to our financial position and the need for additional capital

1. 01We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability
2. 02We require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts
3. 03We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long term
4. 04We have never generated revenue from product sales and may never be profitable
5. 05attracting, hiring and retaining qualified personnel
6. 06In September 2023, we entered into a loan and security agreement (the Original Loan Agreement) with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the Bank), providing us with an aggregate principal amount of up to $50.0 million (the Original Credit Facility)

Risks related to the discovery, development and commercialization of our product candidates

1. 07the approval policies or regulations of the FDA, European Commission or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval
2. 08This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market palazestrant or OP-3136, which would significantly harm our business, financial condition, results of operations and prospects
3. 09Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales
4. 10third-party contractors not performing data collection or analysis in a timely or accurate manner; or
5. 11Because we are pursuing a variety of target indications for palazestrant, we may expend our limited resources to pursue a particular indication and fail to capitalize on indications or additional product candidates that may be more profitable or for which there is a greater likelihood of success
6. 12Even if approved, palazestrant or OP-3136 may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success
7. 13the approval of other new therapies for the same indications
8. 14If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected
9. 15the level of resources that clinical sites have to conduct a growing number of clinical studies
10. 16We intend to develop palazestrant, and may develop OP-3136 or future product candidates, in combination with other therapies, which exposes us to additional risks
11. 17Risks associated with the in-licensing or acquisition of drug candidates could cause substantial delays in the pre-clinical and clinical development of our drug candidates
12. 18Interim, initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
13. 19We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than palazestrant, OP-3136 or product candidates we may develop in the future, our commercial opportunities will be negatively impacted
14. 20Changes in methods of palazestrant manufacturing or formulation may result in additional costs or delay
15. 21Any product candidate we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations
16. 22Guidelines and recommendations published by various organizations can reduce the use of palazestrant, OP-3136 or any future product candidates we may develop

Risks related to regulatory approval and other legal compliance matters

1. 23We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize palazestrant, OP-3136 or any future product candidate we may develop
2. 24Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability could significantly harm our business, financial condition, results of operations and prospects
3. 25The FDA, EMA, the European Commission and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction
4. 26Obtaining and maintaining regulatory approval of palazestrant, OP-3136 or any product candidate we develop in the future, in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of palazestrant, OP-3136 or any product candidate we develop in the future, in other jurisdictions
5. 27Even if palazestrant, OP-3136 or any product candidate we develop in the future, receives regulatory approval, it will be subject to significant post-marketing regulatory requirements and oversight
6. 28The occurrence of any event or penalty described above may inhibit our ability to commercialize palazestrant, OP-3136 or any product candidate we may develop in the future and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
7. 29The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses
8. 30requirements, the FDA, the European Commission or comparable foreign regulatory authorities may seek to withdraw their approval
9. 31We may face difficulties from changes to current regulations and future legislation
10. 32If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, our development plans may be impacted
11. 33analogous state and foreign laws and regulations, such as state and foreign anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers
12. 34with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs
13. 35regulatory investigations and actions, and consumer lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages
14. 36Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
15. 37If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business, financial condition, results of operations or prospects
16. 38Our research and development activities could be affected or delayed as a result of possible restrictions on animal testing

Risks related to employee matters, managing our growth and other risks related to our business

1. 39Unfavorable U.S. and global macroeconomic and geopolitical conditions could adversely affect our business, financial condition and results of operations
2. 40Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
3. 41to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts
4. 42We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators
5. 43In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth
6. 44improving our operational, financial and management controls, reporting systems and procedures
7. 45EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our product in the EU Member States
8. 46Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
9. 47Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
10. 48A variety of risks associated with marketing palazestrant, OP-3136 or any future product candidate we may develop internationally could significantly harm our business, financial condition, results of operations and prospects

Risks related to our intellectual property

1. 49Our success depends on our ability to protect our intellectual property and our proprietary technologies
2. 50proprietary technologies and their uses, our business, financial condition, results of operations and prospects could be significantly harmed
3. 51countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates
4. 52If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected
5. 53The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad
6. 54Intellectual property rights do not necessarily address all potential threats to our competitive advantage
7. 55Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects
8. 56certain similarities with palazestrant. It is possible that one or more of such third parties could pursue patent claims or assert patent claims that allegedly encompass palazestrant
9. 57require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology
10. 58nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign palazestrant, OP-3136 or any future product candidates we may develop processes to avoid infringement, if necessary
11. 59While we may have issued patents that cover palazestrant or OP-3136, it is possible that third parties may have blocking patents that prevent us from marketing, manufacturing or commercializing our own patented products and practicing our own patented technology
12. 60We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
13. 61Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline
14. 62Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party
15. 63Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications or those of our licensors and the enforcement or defense of our issued patents or those of our licensors
16. 64Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect palazestrant, OP-3136 or any future product candidates we may develop
17. 65We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
18. 66Patent terms may be inadequate to protect our competitive position on palazestrant, OP-3136 or any future product candidates we may develop for an adequate amount of time
19. 67In the United States, patent term can be adjusted due to delays that occur during examination of patent applications, which may extend the term of a patent beyond 20 years. There is a risk that we may take action that detracts from any accrued patent term adjustment
20. 68If we do not obtain patent term extension for palazestrant, OP-3136 or any future product candidates we may develop, our business, financial condition, results of operations and prospects may be significantly harmed
21. 69We will not be able to protect our intellectual property rights throughout the world
22. 70Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment, and other requirements imposed by regulations and governmental patent authorities, and our patent protection could be reduced or eliminated for non-compliance with these requirements
23. 71If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations and prospects could be significantly harmed
24. 72If we are unable to protect the confidentiality of our trade secrets, our business, financial condition, results of operations, prospects and competitive position would be significantly harmed
25. 73We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets
26. 74Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others
27. 75If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
28. 76the priority of invention of patented technology

Risks related to our dependence on third parties

1. 77of operations and the commercial prospects for palazestrant or OP-3136 would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely, and our business, financial condition, results of operations and prospects could be significantly harmed
2. 78the misappropriation of our proprietary information, including our trade secrets and know-how
3. 79Agreement, see the sections titled “Business—Clinical Collaboration and Supply Agreement with Novartis” and “Business—Clinical Trial Collaboration and Supply Agreement with Novartis” respectively
4. 80We have engaged in and may in the future engage in additional acquisitions, strategic partnerships or in-licensing opportunities, that may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
5. 81our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs
6. 82We have third-party collaborators for the development and commercialization of palazestrant. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies
7. 83If we decide to establish collaborations in the future but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans

Risks related to ownership of our common stock

1. 84An active trading market for our common stock may not be sustained
2. 85The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment
3. 86sales of our common stock by us, our insiders or our other stockholders; and
4. 87In addition, the trading prices for common stock of other biopharmaceutical companies have been highly volatile as a result of factors unrelated to the specific company or its technology
5. 88Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline
6. 89changes in general market and economic conditions
7. 90Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval
8. 91Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall
9. 92Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to palazestrant, OP-3136 or future product candidates we may develop on unfavorable terms to us
10. 93New or future changes to tax laws could materially adversely affect our company
11. 94Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
12. 95require the approval of the holders of at least 66 2⁄3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our amended and restated certificate of incorporations or amended and restated bylaws
13. 96any action asserting a claim against us that is governed by the internal-affairs doctrine or otherwise related to our internal affairs
14. 97We do not currently intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our common stock
15. 98The requirements of being a public company may strain our resources, result in more litigation and divert management’s attention
16. 99ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial condition, results of operations and prospects may be significantly harmed
17. 100If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline
18. 101Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud